Gefitinib enhances radiotherapeutic effects of 131I –hEGF targeted to EGFR by increasing tumor uptake of hEGF in tumor xenografts

In this study, we sought to determine whether gefitinib could increase the in vivo tumor uptake of human 131I –EGF (131I–hEGF), thereby enhancing the potential of hEGF as a vehicle for EGFR-targeted radionuclide therapy. Western blot analysis was conducted to detect the effects of gefitinib on EGFR expression in human head and neck squamous carcinoma cell line UM-SCC-22B.

Source: Nuclear Medicine and Biology - February 3, 2017 Category: Nuclear Medicine Authors: Lu Xia, He Peng, Luo Zhiqiang, Zhang Xiaoli Source Type: research